Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Update

Tiziana Life Sciences Ltd (NASDAQ:TLSA) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 680,800 shares, a growth of 300.2% from the December 31st total of 170,100 shares. Currently, 1.0% of the company’s shares are sold short. Based on an average daily volume of 348,300 shares, the short-interest ratio is presently 2.0 days.

Tiziana Life Sciences Stock Performance

NASDAQ:TLSA traded down $0.05 on Tuesday, hitting $0.69. The stock had a trading volume of 362,743 shares, compared to its average volume of 1,355,814. The company has a fifty day moving average price of $0.84 and a two-hundred day moving average price of $0.94. Tiziana Life Sciences has a 1-year low of $0.41 and a 1-year high of $1.74.

Institutional Investors Weigh In On Tiziana Life Sciences

An institutional investor recently raised its position in Tiziana Life Sciences stock. Zhang Financial LLC raised its stake in Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 34.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 93,187 shares of the company’s stock after buying an additional 23,800 shares during the quarter. Zhang Financial LLC owned about 0.09% of Tiziana Life Sciences worth $65,000 at the end of the most recent quarter.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.